



Subject: Notification Pursuant to 18 V.S.A. § 4637

To the Office of the Vermont Attorney General:

Dompé US, Inc. hereby notifies the Office of the Vermont Attorney General of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Oxervate ophthalmic solution (cenegermin-bkbj) and Device Kit used for administration	71981-020-01 71981-020-07	December 15, 2018	\$11,800 for a weekly carton that contains 7x1mL vials

For reference, the following information is also provided, pursuant to 18 V.S.A. § 4637(c):

Marketing and Pricing Plans Used at Launch	Estimated Volume of Patients (nationally)	Food and Drug Administration Designation	Date of Acquisition (if applicable)
Not in the public domain or publicly available (therefore, not required to be reported pursuant to 18 V.S.A. § 4637(d)).	Neurotrophic keratitis is classified as an orphan disease and thus is considered to affect fewer than 5 individuals per 10,000. Oxervate was granted Orphan Drug Designation by the U.S. FDA's Office of Orphan Products Development in July 2014.	Oxervate was granted Fast Track Status, Breakthrough Therapy Designation, and then approved under Priority Review by the U.S. FDA.	Not applicable; the drug was developed by the manufacturer.

www.dompe.com